Latest Tigatuzumab Stories
LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
DALLAS, February 21, 2014 /PRNewswire/ -- RnRMarketResearch.com offers cancer monoclonal antibodies market (mABs) research reports covering pipeline analysis as well as
ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) (IMUC), a biotechnology company, today announced that the company's president and chief executive officer, Manish Singh, Ph.D., will make a company presentation at the Rodman & Renshaw 10th Annual Healthcare Conference.
REDWOOD CITY, Calif., Nov. 4 /PRNewswire/ -- OncoMed Pharmaceuticals, a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today announced the successful completion of the final tranche of its Series B financing round, raising $93 million.
ImmunoCellular Therapeutics, a biotechnology company, has received two separate US patents relating to the company's monoclonal antibody therapeutics.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, announced the issuance of two separate U.S. patents relating to the company's monoclonal antibody therapeutics. Patents No. 7,435,415 and No.
ImmunoCellular Therapeutics, a biotechnology company, has signed a research agreement with UK-based biotechnology company Antitope for the humanization of IMUC's monoclonal antibodies.
ImmunoCellular Therapeutics has signed a research agreement with George Mason University for the development of a blood test to detect small cell lung cancer and pancreatic cancer using IMUC's monoclonal antibody technology.
- A political dynamiter.